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The EORTC Cancer in the ElderlyTask Force (ETF) aims to develop, conduct, coordinate
and stimulate research on elderly patients with cancer. Towards this goal, the ETF
has established close interactions with disease-oriented EORTC groups by having
representatives from most of these groups attend the ETF meetings. In addition, the
ETF reviews every new protocol for elderly-speciﬁc questions within the protocol
review process of the EORTC aiming to reduce ageism within study protocols. Since
2006, the ETF decided to focus on three aspects: open a discussion on speciﬁc
methodology for clinical trials in the older population; create a common language for
describing heterogeneity between older individuals, the EORTC minimal dataset for
geriatric assessment in older cancer patients; and develop speciﬁc clinical trials in
the older population. This article reports the achievements of the ETF in these three
domains and discusses its future strategies.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction
As a result of an increasing life expectancy, the incidence
of cancer cases diagnosed in the older population is
rising. Indeed, cancer incidence is 11-fold higher in
persons over the age of 65 than in younger ones. Despite
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this high incidence of cancer in older patients, solid
data regarding the most appropriate approach and best
treatment for older cancer patients are still lacking
mostly due to underrepresentation of these patients in
prospective clinical trials.
Geriatric oncology is a relatively recent ﬁeld which
probably dates to the early 1980’s. 1 The European
Organization for Research and Treatment of Cancer
(EORTC) has currently deﬁned senior adult oncology
as one of its priorities and has established a Cancer
in the Elderly Task Force (ETF). The ETF is one of
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the youngest research groups of the EORTC, and was
ofﬁcially established in 1992 under the name of ‘EORTC
Neoplasia in the Elderly Study Group’ with Silvio
Monfardini acting as the ﬁrst chair. However, before
this date there were initiatives led by EORTC members,
among whom Ian Fentiman deserves to be mentioned
with respect to his editorial on why older cancer patients
are not receiving the therapy they need. 2 This was
followed in October 1990 by a joint symposium with
the United States National Cancer Institute organized
by Monfardini and Chabner, where problems identiﬁed
in elderly cancer trials were discussed. This resulted
in a consensus paper with deﬁned goals which remain
relevant 20 years later. 3,4 Within the EORTC disease-
oriented groups, a few clinical trials directed towards
the older population were set up, 5−9 but there was
no consistent global approach towards older cancer
patients. The ETF initially had an advisory function
towards the disease-oriented groups. Subsequent ETF
Chairs were, respectively, Matti Aapro, Ulrich Wedding,
and presently Hans Wildiers.
Currently, the ETF consists of 75 members and meets
physically at least twice a year. The ETF aims for
close interaction with disease-oriented EORTC groups
by having representatives from most of these groups
attend the ETF meetings. In 2006, the EORTC and the ETF
decided to focus on three aspects: (1) open a discussion
on speciﬁc methodology for clinical trials in the older
population; (2) create a common language for describing
heterogeneity between older individuals (both in older
cancer patient speciﬁc trials and in general population
trials); and (3) development of speciﬁc clinical trials in
the older population.
In addition the ETF reviews every new protocol for
elderly-speciﬁc questions within the protocol review
process of the EORTC. With this approach ageism within
study protocols is reduced.
We report here on the achievements of the ETF in these
three domains and on future perspectives.
2. Development of speciﬁc methodology for clinical
trials in the older cancer patients
Old age has often been perceived as a ‘contraindication’
for drug and treatment strategy development. In older
patients comorbidity is often present. Certainly in unﬁt
elderly, there is generally a decreased tolerance of
therapy with higher risk of ‘toxic deaths’, and (sometimes
unrelated) serious adverse events that can harm early
drug development signiﬁcantly. This contrasts with the
fact that the majority of cancer patients are ‘old’. Drugs
and other treatments are thus generally developed in
‘healthy young patients’ (and a few ﬁt older patients)
but only administered to ‘less healthy older patients’
following registration.
An important concept is the fact that ﬁt older patients
can often tolerate and receive identical treatments
as younger patients. On the other hand, vulnerable
and frail patients have decreased capacity to tolerate
treatments, and cannot receive identical treatments
as younger patients in many oncological settings
(e.g. high-dose cisplatin or anthracycline; concomitant
radiochemotherapy; major surgery). If one designs
clinical trials in older patients, the question often arises
what would be the appropriate control arm. If one
would take the ‘standard treatment as in younger’ as
standard arm, this would probably bias the study towards
dominant inclusion of ﬁt older patients only who would
be expected to tolerate standard therapy. If one would
take ‘less toxic treatments’ as control arm, it could be
argued that these are not really standard arms, and that
the more ﬁt patients might be ‘undertreated’. It is quite
difﬁcult to escape from this “Catch 22” situation.
The ETF believes that older cancer patients provide
speciﬁc opportunities for drug and treatment develop-
ment. Speciﬁc drugs/regimens or study designs can be
investigated in older patients that would not be possible/
acceptable in the ‘younger population’. Examples are:
(1) monotherapy of new drugs can be acceptable in an
early stage in older patients; (2) since there is no real
standard therapy for (unﬁt) older patients in general,
any new drug/combination with good safety proﬁle and
improved efﬁcacy compared to ‘one of the possible
standard therapies’ might become a new standard of
care; (3) placebo arms without ‘active’ therapy can be
more often acceptable in older patients. So there are
big opportunities for drug development in the older
population. Since the majority of cancer patients are
old, there is a huge potential market for new drugs and
strategies, and at present there is much less competition
in ‘older’ patients than in younger patients (for instance:
in HER2-positive breast cancer there are a multitude of
upcoming drugs, but to date none of them has been
studied speciﬁcally in unﬁt older individuals).
An important aspect is that new drugs and treatment
strategies in older individuals should have limited
toxicity; Quality of life (QoL) is important for cancer
patients in general, but even much more for older
individuals! If a therapy is too toxic and decreases QoL
in a signiﬁcant proportion of older patients, many would
probably not choose such a treatment if they knew the
pros and cons before deciding.
The ﬁrst important achievement of the ETF is the
development of speciﬁc methodology for clinical trials
in the older cancer population. Two papers regarding
standardization and unmet needs of clinical trials in
older population were published in 2010.
The ﬁrst publication was an EORTC Elderly Task Force
Position Paper 10: Approach to the Older Cancer Patient,
published in European Journal of Cancer. The purpose of
this paper was to focus on the inﬂuence of age on
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cancer presentation and cancer management in older
cancer patients and to provide suggestions on clinical
trial development and methodology in this population.
For the second, the EORTC ETF organized a workshop
on clinical trial methodology in older individuals
which was held at EORTC Headquarters in December
2009. A summary of this international multidisciplinary
meetings is published in Annals of Oncology. 11 Focusing
on improvement of cancer treatment in older patients,
this workshop reached the following conclusions:
• Besides the “classical” efﬁcacy end-points (overall
survival, time to tumor progression, progression-free
survival) cancer clinical trials in older patients should
have an assessment of the impact of treatment on QoL,
functional status and independence of the patient, key
issues rated as priority by older cancer and non-cancer
patients. These issues could be incorporated either as
co-primary end-points or as composite end-points (in
combination with efﬁcacy end-points).
• The participants of the workshop agreed on the use of a
Minimum Data Set for the assessment of global health
status and functional status in older cancer patients
(see below).
• The panel had three recommendations for designing
and reporting clinical trials in the future:
(1) Obligatory reporting of age related subgroup
analysis (with a preplanned analysis).
(2) Obligatory post marketing studies in vulnerable and
frail older patients.
(3) Obligatory inclusion of a minimum ‘geriatric’ data
set for senior adult patients in registration trials
and post-marketing trials.
The ETF will continue with this process and try to
establish a worldwide dialogue on this topic with the goal
of combining efforts and using comparable strategies
in different parts of the world (allowing cross-trial
comparisons). A second ETF multidisciplinary workshop
with European and now also American representatives
on clinical trial methodology will be held on 03 November
2011 during the SIOG (Socie´te´ Internationale d’Oncologie
Ge´riatrique) conference in Paris.
Awareness at the level of regulatory bodies is a key
element in the development of more ‘elderly directed’
clinical trial methodology in the frail and vulnerable
patients. The current chairman, Hans Wildiers, has
recently been appointed as member of the EMA GEG
(European Medicine Agency Geriatric Expert Group),
where a strategy for better investigation of drugs in the
older population will be on the agenda.
3. EORTC minimal dataset for geriatric assessment
in older cancer patients
Over the last few years there has been a great deal
of interest in the development of objective assessment
tools to measure the “ﬁtness” of older patients with
cancer which may be used to enhance management
decisions. Much of the research in this area has
centered around the development of “Comprehensive
Geriatric Assessments” which aims to describe the
characteristics of a patient in a number of domains
(such as functional status, co-morbidities, nutrition).
However different groups with an interest in geriatric
oncology have proposed different formats of the so-
called Comprehensive Geriatric Assessment, meaning
that it will be difﬁcult to compare data and to apply
ﬁndings to practices at a local level.
In response to this the EORTC ETF has established a
standardized Elderly Minimal Dataset (MinDS) with the
purpose of harmonizing the collection of data relevant
to older patients and to enable cross-study/practice
comparisons in the future. It was emphasized that the
dataset does not need to be restrictive nor compre-
hensive but rather should form the backbone upon
which individual investigators could add assessment
tools pertinent to the particular study or local speciﬁc
interests. It is also anticipated that this dataset will
evolve over time with addition, removal, or reﬁnement
of tools as more data become available. A key aspect of
the dataset is that it includes instructions for completion
of the tools as there are some controversies in this area.
The MinDS includes four elements: Charlson Co-
morbidity Index (CCI), G8 Geriatric Assessment Screening
Tool, Instrumental Activities of Daily Living (IADL), and
Social Situation. It is published (as an appendix) in the
Annals of Oncology paper mentioned above. 11 The G8 is a
geriatric screening tool initially developed and studied
in France aiming to identify which patients require a
full geriatric assessment. 12 The Oncodage study, a large
multicenter French study, has prospectively validated the
G8 with optimal cutoff at 14 (on a total score of 17)
and is currently the only prospectively validated geriatric
screening tool in oncological patients (submitted for
publication). Detailed information on the G8 and other
evaluation instruments can be found at http://siog.org/
4. Development of clinical trials in the older
population
A few EORTC disease-oriented groups were pioneers in
performing trials in older patients in the 1990’s. The
EORTC Lymphoma Group had innovative trials including
a substantial number of frail elderly patients. 6,7 The
EORTC Breast Cancer Group performed a randomized
trial in older patients with early breast cancer comparing
surgery with or without tamoxifen. 8 In 2002 an ETF
working party concluded after review of existing data
that for some speciﬁc cancers, dose intensiﬁcation with
the use of G-CSF improved survival in older cancer
patients. 9 Despite these efforts, older patients have
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generally been under-represented in clinical cancer
trials, meaning that there is very limited evidence for the
treatment of the population of patients in whom cancer
is most prevalent. 13,14
In order to directly address this problem the ETF has
developed a number of clinical study proposals which
have been submitted to the EORTC protocol review
committee (PRC). It is not easy to ﬁnd ﬁnancing for
clinical trials in older cancer patients, but the ﬁrst trial
of the ETF has obtained PRC approval in early 2011, and
the trial is expected to open and recruit in the coming
months. This study in colorectal cancer (EORTC 40085–
75083) is a phase III randomized trial of 5-FU + cetuximab
versus 5-FU alone in “unﬁt/frail” patients with metastatic
colorectal cancer and wild-type k-ras status. Frailty or
unﬁtness is deﬁned as an age of 80 or over, or lower age
(70−80) but with functional limitations or signiﬁcant co-
morbidities. The trial will be performed together with
the EORTC Gastrointestinal Tract Cancer Group. The
main objective is to determine if these patients derive
beneﬁt in terms of progression-free survival from a
regimen consisting of chemotherapy plus a biological
agent with limited toxicity. Accrual of 228 patients (136
k-ras wild type) is required. Other proposals in breast
cancer and lung cancer are currently in advanced stage
of development.
Within the framework of these trials, the ETF is
planning to start a central biobank for peripheral
blood to study potential ageing biomarkers. Given the
paucity of large clinical trials currently running in the
older population, it is of crucial importance to create
a European biobank of biological samples which can
be used for future research projects. In a ﬁrst step
this biobank will involve the collection and storage of
blood samples. Ageing markers of interest are: telomere
Length, expression of p16 in peripheral leukocytes,
circulating IL-6, TNF-a and IL-10, CMV IgG and IgM
and SNP’s in FOXO3A and other ageing related genes.
A template protocol for biobanking has been established
that can be built into different clinical trial protocols.
An FP7 grant on this topic has been submitted in
October 2011 for this purpose.
The ETF has also collaborated with the EORTC Quality
of Life Group in the development of tool speciﬁcally for
older cancer patients, the QLQ-ELD15 scale. 15 This QoL
scale will also be integrated in future older cancer patient
studies. The ETF has also published guidelines on the
treatment of lung cancer 16 and colorectal cancer 17 in
older individuals.
The EORTC Clinical Research Groups are starting to see
the added value of the ETF and its program of speciﬁc
older cancer trials. Integration of the available elderly
tools for an elderly subgroup in their general population
studies is more often taken into consideration.
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